Home \ News \ Vaccines and Related Biological Products Advisory Committee – 10/26/2021

More

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Vaccines and Related Biological Products Advisory Committee – 10/26/2021

NOW PLAYING

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

CDC Statement on ACIP Booster Recommendations

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Tense decision-making as CDC joins FDA in recommending Pfizer booster shot for 65 & up, people at high risk and those with occupational exposure to COVID-19

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Ten scientific reasons in support of airborne transmission of SARS-CoV-2

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months, study shows

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Top COVID-19 doctors and scientists privately asked the Biden administration to scrap its booster-shot plan, report says

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Is my immunity waning? Doctors advise Pfizer vaccine recipients not to worry

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

FDA review finds Moderna’s booster dose of its coronavirus vaccine strengthens disease-fighting response

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Myths and Facts about COVID-19 Vaccines

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

TENSE DECISION MAKING BETWEEN CDC AND FDA

Vaccines and Related Biological Products Advisory Committee – 10/26/2021

TVNET3 November 2, 2021 3:56 pm

Join the U.S. Food and Drug Administration for an upcoming meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss newly available data for the currently available COVID-19 vaccines.

The committee will meet to discuss a request to amend Pfizer-BioNTech’s Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age.

Category: News

About The Author

TVNET3 -